Vertex Pharmaceuticals Edges Out Amgen in Biotech Showdown
Biotech investors often weigh the pros and cons of established giants against innovative specialists. Two companies that frequently come up in discussions are Amgen (AMGN) and Vertex Pharmaceuticals (VRTX).
Amgen operates as a global pharmaceutical titan with a massive portfolio spanning multiple therapeutic areas, including oncology, inflammation, and rare diseases. In FY 2025, revenue reached nearly $36.7 billion, representing growth of approximately 9.9% compared to the previous year. The company reported net income of roughly $7.7 billion for the period.
On the other hand, Vertex Pharmaceuticals focuses on transformative medicines for life-threatening diseases and has maintained a dominant global franchise in cystic fibrosis therapies. In FY 2025, revenue reached nearly $12.1 billion, with a growth rate of approximately 9.6% year over year.
One key difference between the two companies is their debt-to-equity ratio. Amgen's is approximately 6.3x, indicating a higher reliance on borrowing, whereas Vertex Pharmaceuticals' is around 0.2x, providing significant financial flexibility.
The author concludes that while Amgen deserves credit for running a dependable business, Vertex Pharmaceuticals is the better choice due to its faster growth and expanding pipeline. The company's cystic fibrosis drugs now reach nearly all patients with the disease, and it has recently completed an acquisition adding a kidney disease drug awaiting FDA approval.
The author notes that Amgen's steady income and growth make it a strong choice for investors prioritizing these factors, but ultimately recommends Vertex Pharmaceuticals due to its potential for further expansion and growth.